ArticleOncotarget2025

Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib.

Jinah Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.